Organic Active Ingredients TRIZ Cases

Local heparanase inhibition targets lymphocytes at the transplant site to prolong allograft survival while limiting systemic toxicity.

This case combines alternating electric fields, temozolomide, and checkpoint inhibition for biopsy-only glioblastoma, addressing poor survival when surgery is not feasible.

Enzyme casein coagulation, thermal treatment, ultrafiltration, and dialysis remove milk contaminants while preserving EV function.

Peptide vaccines can lose efficacy through enzymatic breakdown and poor tissue access; HDL nanodiscs shield cargo and improve delivery to lymphoid organs.

Deformable nano-scale vehicles tune size, charge, and surface properties to cross skin and the blood-brain barrier while limiting systemic toxicity.

Stable topical Compound I forms penetrate cervical layers and metabolize to PMEG for HPV neoplasia treatment without surgery.

See how silk fibroin, hyaluronic acid, and PEG or PPG crosslinking tune filler properties for soft-tissue defects while reducing inflammatory responses.

Functional seams guide orodispersive tablets into equal-mass sub-doses, reducing material loss from uneven conventional breaks.

BTK inhibitors can block mast cell and basophil degranulation during acute allergic reactions, limiting mediator release and escalation.

Combining cabotegravir with a gp120 binding protein uses distinct antiretroviral mechanisms to inhibit HIV-1 replication and address drug resistance.

Selective PARP1 inhibition preserves antitumor activity while avoiding PARP2-linked hematological toxicity in cancer treatment.

Rapid serum exposure from immediate-release huperzine can trigger nausea and vomiting; an ethyl cellulose coating extends release for twice-daily dosing.

This case uses an optically active azabicyclo ring derivative to inhibit menin-MLL fusion protein binding in mutation-associated cancers.

Bifidobacterium pili bind resistant starch granules, helping surface-anchored hydrolases improve degradation and gut microbiome modulation.

Specific integrin-activating peptides target low embryo implantation rates, with an artificial uterus enabling reliable medicament screening.

A non-therapeutic vitamin B12 approach helps maintain muscle mass, increase fiber size, and improve function during aging.

Combining an anti-PD-L1 aptamer with CpG oligonucleotide, the complex enables systemic dosing, dual immune activation, and reduced multi-drug treatment burden.

This case shows how sodium, potassium, and calcium salt forms of a thio-substituted compound target URAT1 to reduce uric acid levels.

Low-water-solubility aniline derivatives challenge vaginal dosing; a nonionic surfactant in the granules supports dissolution and bioabsorbability.

A linear DNA-binding compound linked to TPP targets mitochondrial DNA, reduces mutant copy numbers, and induces mitochondrial autophagy.

Cetagliptin free base is a viscous oil; crystalline phosphate salts improve druggability while offering low hygroscopicity, stability, and oral bioavailability.

A pH-dependent coating limits metformin release in acidic conditions, then enables rapid intestinal dissolution to balance tolerance and efficacy.

Novel purine compounds vary substituents and ring structures to selectively inhibit PI3K-delta where existing treatments lack precise target modulation.

Continuous isomaltulose before glucose intake helps limit postprandial arterial stiffness, measured by brachial-ankle pulse wave velocity.

Reducing fermentation increases 2'-FLol alongside 2'-fucosyllactose, enabling purified prebiotic solids with a more robust composition.

Tasquinimod targets S100A9 and inflammatory pathways to improve blood counts and hematopoietic function in MDS.

Covalent compounds target CDK7 residue Cys312 to overcome kinase-family similarity and improve selective inhibition with reduced toxicity.

These compounds inhibit KIF18A ATPase activity to stop mitotic progression and promote apoptosis in cancer cells.

Formula (I) compounds use targeted substituents to improve PI3Kγ inhibition, isoform selectivity, and aqueous solubility.

With LKB1 sensing mechanisms unclear, small molecules targeting 3-phosphoglycerate, 2-phosphoglycerate, and pyruvate modulate AMPK kinase activity.

Separate syringes mix hyaluronic acid or hydrogel with hydrogen peroxide at use, avoiding long premixing and decomposition.

Conventional agents may not increase beneficial bacteria; Galdieria-derived glycogen raises bifidobacteria, butyric acid bacteria, and α-diversity.

Specific cyclyl and heterocyclyl substitutions tune ACKR3 modulation for cardiovascular and platelet disorders.

By inhibiting KIF18A motor activity on microtubules, small molecules disrupt mitotic spindle dynamics as a targeted cancer treatment approach.

Controlled low-energy stirring forms homogeneous lipid nanoparticles with narrow size distribution while limiting active-ingredient degradation.

Controlled crystallization creates forms A–I with improved stability, solubility, and handling for pharmaceutical dosage preparation.

Controlled coating onset and weight gain keep release at ≤15% in pH 4.5 while enabling ≥85% dissolution in pH 6.8 within 20 minutes.

See how a heterocyclic pyrimidine derivative targets ALK and EGFR mutations in NSCLC, including L1196M and C797S.

Poor water solubility and oxidation challenge topical sirolimus delivery; DMSO and propylene carbonate stabilize formulations.

Nonaqueous carriers such as propylene glycol help keep hydrocortisone oral liquids stable for accurate dosing.

Heterocyclic nitrogen in the aromatic ring supports oral absorption and metabolic stability while one compound inhibits both FGFR and VEGFR.

Hydrophilic solvents can limit delivery; this ibuprofen formulation uses solid and liquid lipids to form micelles for intestinal and immune-cell absorption.

This case addresses weak α7 receptor affinity in cyclic imine toxins by combining receptor binding with cytotoxic and apoptotic activity.

The case uses selective M1/M4 citrate salts to reduce nausea, gastrointestinal effects, and bradycardia linked to M2/M3 activation.

New molecular structures target cathepsin B while improving drug-like properties and blood-brain barrier access for CNS disease therapy.

Limited SIRT1 activator benefit is addressed with a pyrimidopyrimidinone compound that lowers amyloid, Tau, and α-synuclein expression.

A pH 5.0–7.0 coating helps sustain compound (I) blood levels, reducing toxicity risk and supporting once- or twice-daily dosing.

These substituted bicyclic compounds inhibit DDR1 kinase activity, extending potential treatment beyond symptomatic relief for renal and fibrotic diseases.

By staying neutral in circulation and becoming cationic in acidic endosomes, ionizable lipids support lower-toxicity mRNA delivery to lymph nodes.

Limited treatment options for viral infections are addressed with phosphatidylcholine, anionic phospholipids, and a cyano carba-nucleoside analog.

Dual blockade of IGF and AR signaling pathways overcomes castration resistance in prostate neoplasia treatment.

Asymmetric organometallic catalyst enables stereoselective hydrogenation of dihydroisoquinoline precursors.

Segmented molecular structures resolve the contradiction between reliable modulation and poor brain penetration, improving treatment outcomes.

Injectable linezolid hydrogel treats Modic change infections locally, eliminating systemic side effects and improving patient compliance.

Combining an alkylating histone-deacetylase inhibitor fusion molecule with a class III receptor tyrosine kinase inhibitor creates synergistic anti-cancer activity.

Pemafibrate avoids renal excretion to treat hypertriglyceridemia without statin interactions.

Replacing centrifugation with temperature-controlled phase separation enables scalable phospholipid concentrate production from bird breast meat.

Applying local quality through ethnicity-specific dosing improves treatment reliability while managing side effects.

Segmented subcutaneous micro-pellets distribute medication to reduce injection site reactions while maintaining extended treatment duration.

Specific compounds bind the SARM1 catalytic pocket to block NAD+ depletion and prevent axonal degeneration in neurodegenerative diseases.

Cyclic N-acyl O-amino phenol pro-drugs overcome rapid release and toxicity issues by cleaving the N-O bond under hypoxic conditions.

Oral aspartic acid combination therapy replaces painful gonadotropin injections to improve sperm production while lowering treatment costs.

Segmenting genetic testing for PDGFRB and NOTCH3 mutations resolves the trade-off between diagnostic precision and testing complexity.

Aminopyrimidinone compounds inhibit IRAK-4 kinase activity, modulating inflammatory responses in rheumatoid arthritis and IBD.

Organocatalyzed polythioether coatings prevent bacterial adhesion and biofilm formation, resolving long-term stability issues in implantable medical devices.

Combination therapy with belvarafenib, cobimetinib, and atezolizumab targets the MAPK pathway and immune checkpoint to inhibit tumor growth.

Formula IV uracil compounds inhibit c-MET and AXL to reduce tumor growth while resolving toxicity trade-offs.

Nicotiana benthamiana platforms generate homogeneous anti-CD20 antibodies, resolving mammalian cell heterogeneity to enhance clinical efficacy.

Specific organic acids buffer the environment to suppress hydrolysis and maintain chemical integrity.

Segmented TLR7, 8, and 9 antagonism via hydropyrazino isoquinolines reduces autoantibody production while minimizing systemic toxicity.

A microsuspension of an MDM2 inhibitor with surfactant and tonicity agent delivers therapeutic doses.

Cyclodextrin inclusion complexes stabilize naproxen sodium against degradation while eliminating hyperosmolality and hemolysis risks from high excipient loads.

Pre-screening TMEM173, TLR6, and TLR10 variants directs STING agonist therapy to patients with responsive genetic profiles.

Indolone compounds modulate TARP gamma 8 associated AMPA receptor complexes to treat CNS disorders.

A new alpha-crystalline form of carbabenzpyride achieves high purity through controlled condensation and crystallization steps.

A hemodialysis circuit applies localized electric fields and siRNAs to destroy circulating tumor cells in extracorporeal blood.

Intranasal Thevetin A and B nasal spray bypasses oral first-pass metabolism to provide sustained migraine relief without systemic side effects.

A non-covalent self-organizing hydrogel matrix uses covalent polymer-peptide conjugates to form stable biomaterial structures.

Macrocyclic pyrazol[3,4-d]pyrimidin-3-one derivatives inhibit Wee1 kinase to selectively sensitize cancer cells while sparing normal tissues.

3,3'-Diindolylmethane derivatives block ROS-induced hepatic stellate cell activation to reduce collagen deposition and treat fibrosis.

Heterocyclic modifications extend half-life and selectivity, resolving instability and infusion risks in pulmonary arterial hypertension treatment.

Modular compounds target the Sec61 channel seam to block nascent chain translocation, resolving selectivity and manufacturing trade-offs.

Black currant and bilberry extracts inhibit measles virus replication via synergistic anthocyanins, resolving toxicity trade-offs in antiviral treatments.

Osmotic controlled release dosage form maintains steady plasma concentrations of apixaban, reducing peak levels and side effects.

A dichlorophenylamide salt of carbopentoxysulfanilic acid overcomes resistance in herpes simplex virus types I and II treatment.

Small molecule intermediaries modulate Wnt components, resolving therapy reliability gaps.

Acrylic polymer blends with polyisobutylene and SIS block copolymers deliver controlled drug flux in flexible finite forms.

Polymer-conjugated topoisomerase I and liposomal topoisomerase II inhibitors maintain prolonged therapeutic pressure while minimizing severe side effects.

Administering 2-hydroxyoleic acid stimulates SMS2 activity to promote PKCδ-mediated apoptosis of self-reactive B cells.

A bimodal pharmaceutical carrier delivers cannabinoids transdermally while depositing skin protecting ingredients topically.

Pharmaceutical solid preparation combines compound I with colorants to absorb harmful light and prevent degradation.

Alpha-7 nicotinic acetylcholine receptor modulators reduce dyskinesia severity and frequency in Parkinson's disease patients.

5-amino-2,3-dihydro-1,4-phthalazinedione mitigates pulmonary edema and inflammation to shorten ventilation duration.

An aqueous aprepitant formulation uses a surfactant to solubilize the drug while maintaining stability against degradation.

Topical vanadate derivatives activate hair follicles into the anagen phase, inducing regrowth without severe side effects.

Simplifying molecular structure via extraction enables aminoquinoxaline derivatives to penetrate the blood-brain barrier without complex hydrophobic chains.

Optimized long double-stranded RNAs with specific 3' overhangs achieve efficient gene silencing while minimizing antiviral immune responses.

Fluorinated ethyl side-chains on quinoline cores boost PI3K inhibitory activity while resolving selectivity trade-offs against other human kinases.

Stable calcium 5-methyltetrahydrofolate formulations bypass impaired methylation pathways in MTHFR polymorphisms by delivering bioactive compounds directly.

An iontophoresis device uses an integrated dielectric layer to shunt electrical current and enhance medicament penetration efficiency.

Bicyclic GPR40 agonists stimulate insulin release only when glucose levels rise, targeting pancreatic beta cells to improve metabolic control.

Pulmonary delivery of pure 5R glitazone reduces systemic cardiovascular risks while treating inflammatory respiratory diseases.

Formula I compounds modify heterocyclic ring structures to inhibit the YEATS domain, addressing insufficient therapeutic efficacy in blood cancer treatment.

Porous polysaccharide networks reduce glucose bioaccessibility while retaining fatty acid and protein levels to manage obesity risks.

Imidazole amine compounds resolve solubility and bioavailability trade-offs by inhibiting p70S6K and Akt kinases.

Pyrido[2,3-d]pyrimidine synthesis uses chiral intermediaries to resolve stereoisomer enrichment trade-offs while maintaining reaction speed.

Combines two direct-acting antiviral agents to clear hepatitis C virus infection without interferon or ribavirin.

Water-alcohol crystallization eliminates acetone solvent volume while maintaining purity above 99.4 percent.

Allosteric modulators selectively activate the M4 muscarinic acetylcholine receptor to enhance cholinergic signaling.

Acidic hydrogenation converts impurities during reaction, eliminating residual solvent and drying steps.

A topical anti-pruritic formulation combines an occlusive skin conditioning agent with an organosiloxane to enhance active ingredient delivery.

Pyridine derivatives bearing a phosphonoxymethyl group bypass drug resistance pathways by inhibiting fungal GPI biosynthesis, improving solubility and safety.

Multi-omics data analysis identifies novel drug candidates, expanding discovery beyond prior knowledge to improve response rates.

Selective benzamide compounds target inflammatory pathways to resolve side effects from broad immunosuppression in IBD treatment.

Plant-derived polyamine extract stabilizes skin cell membranes to prevent temperature stress damage and preserve elasticity.

Novel GPR 119 agonist compounds regulate satiety and lower blood glucose levels through targeted receptor activation.

A recombinant vaccinia virus expresses hemagglutinin genes from novel influenza strains to induce immune activation.

Seriniquinone derivatives resolve melanoma treatment gaps by inducing autophagy and inhibiting dermcidin protein activity to promote cell death.

N1-cyclic amine-N5-substituted phenyl biguanide derivatives activate AMPK to inhibit cancer cell proliferation and lower blood glucose levels.

Pyrido[3,4-d]pyrimidine-2,4-dione derivatives inhibit TRPC5-mediated ion flux to alleviate hyperexcitability in neuropsychiatric disorders.

Pyrimido[4,5-d]pyrimidin-2-one derivatives achieve selective kinase inhibition by optimizing local substituent patterns to target LCK and other kinases.

Enzyme-modified polysaccharide complex inhibits angiogenesis through concentration-dependent reduction of tube formation and cell migration.

Formula I compounds activate retinal precursor cells to regenerate tissue, reversing degeneration where current therapies only manage symptoms.

Polyol and citrate buffers stabilize ketoprofen, amitriptyline, and oxymetazoline in liquid injection formulations.

Purine derivatives modulate Toll-Like Receptor 7, resolving trade-offs between metabolic stability and solubility.

Serlopitant reduces pruritus intensity while minimizing drug-drug interactions compared to aprepitant.

Amorphous pitolisant solid dispersion resolves stability versus solubility trade-offs using cyclodextrin excipients.

Ultrasound-triggered release of dual liposomes reduces inflammation and neointimal growth, minimizing chronic anticoagulant therapy needs.

Phosphorus prodrugs overcome antiviral agent limitations by activating in cancer cells to exert antitumor activity.

Blocking IL-6 signaling with anti-IL-6 receptor antibodies while administering gemcitabine overcomes immunosuppression to improve long-term survival rates.

Fusing a saturated carbon ring to a pyridone core in a quinoline derivative yields strong Axl inhibition while reducing CYP side effects.

Alpha-tea salts crystallize to resolve liquid crystal contradictions, enabling stable cancer treatments.

Erythromycin and related macrolides inhibit aberrant RNA splicing to restore normal protein production.

Oral creatine, leucine, zinc, calcium, and magnesium composition enhances pelvic floor muscle strength to resolve insufficient cure rates from exercise alone.

Replacing animal-derived trypsin with recombinant human trypsin eliminates adventitious contamination risks while maintaining infectious titers.

1H-indazole-3-carboxamide compounds selectively inhibit glycogen synthase kinase 3 beta activity.

Inducible tg83 promoters drive CFTR mRNA transcription via dexamethasone signaling.

Optimized chemical modifications and lipid conjugation reduce cytotoxicity while maintaining biological activity for hepatitis B treatment.

Replacing calcium cations with L-leucine ethyl ester eliminates polymorphic instability and water absorption in folic acid salts.

A mussel lipid and krill oil combination inhibits pro-inflammatory mediators through synergistic marine lipid action.

Novel preparation methods for Icotinib utilize benign reagents to achieve mild reaction conditions.

Compounds inhibit AhR-mediated gene induction to prevent UVB damage without surface layer abrasion.

Multiwarhead nucleic acid aptamers link fluorosulfonyl groups via azide-alkyne click chemistry to enable covalent binding.

Merges insulin glargine and lixisenatide into one injection to simplify regimens while improving glycemic control.

Merges MEK and ERK blockade to overcome SHP2-mediated resistance in FLT3-ITD mutated acute myeloid leukemia.